Search

everythinglearnresearchcommunity

for

Search:↓

A user shared their 5-month progress using topical minoxidil and finasteride for hair loss. Others congratulated and suggested a haircut style.

Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.

The conversation discusses using P5P (Vitamin B6) supplements to reduce elevated Prolactin levels and concerns about its potential effect on increasing DHT levels. The user is not currently using finasteride or any anti-androgens.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

A user shared impressive hair regrowth results after using 5% topical minoxidil twice daily and 1mg oral finasteride daily for five months. The user reported no side effects and did not use additional treatments like PRP or dermarolling.

Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.

A user achieved significant hair regrowth from Norwood 3 to a dense Norwood 2 after five months using oral dutasteride, oral minoxidil, and a topical solution with minoxidil, retinoic acid, and hydrocortisone. The user reported no side effects and found the topical treatment especially effective for the hairline.

Glycine may upregulate 5AR, potentially affecting hair. Users suggest using Finasteride to manage hair loss concerns.

Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.

Hair restoration after FUE surgery, with discussions on using finasteride, dutasteride, and oral minoxidil for hair maintenance and growth. Users share experiences with these treatments, noting varying side effects and effectiveness.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

A user shared their 5-month progress using Finasteride (1mg daily) and 3 months on Oral Minoxidil (5mg daily) for hair regrowth, reporting significant improvement and no side effects. They experienced initial shedding with Minoxidil but saw substantial regrowth, encouraging others to try these treatments.

A user shared their 5-month hair loss treatment progress using 1mg finasteride, topical minoxidil, biotin, Nizoral shampoo, and weekly dermarolling. Replies noted the user's hair was already thick, and there was interest in trying topical minoxidil.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

People are discussing the use of an untested hair loss treatment called PP405, which is not available on the grey market. Some users are trying a mimic formulation called HP3, reporting thicker hair but no new growth yet.

A user shared progress after 5 months on oral finasteride (1mg) and minoxidil (2.5mg), noting improvements despite minimal temple growth. They experienced shedding initially but reported no side effects, and others shared similar experiences and additional treatments like hair serums.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

Collagen peptides are recommended for hair and skin benefits, with users noting improvements in hair and skin health. However, evidence on their effectiveness for hair growth is inconclusive.

A person's successful 5-month hair loss treatment using Finasteride and Minoxidil. Questions and comments from others focus on the source of the treatments and application methods.

Pelage Pharmaceuticals' PP405, a new hair loss treatment, was recognized by Time Magazine as one of the best inventions of 2025. The conversation expresses optimism about the recognition of this in-development treatment.

A 23-year-old user shared progress pictures after 5 months of using 1.25 mg finasteride, 2x daily topical minoxidil, weekly derma stamping, and occasional Nizoral and mixed topical for dandruff. They report reduced shedding and seek advice on when to confidently grow out their hair.

Microneedling combined with latanoprost may convert vellus hairs to transitional or terminal hairs. The user suggests using oral minoxidil to increase vellus hair, then applying a high concentration of latanoprost with microneedling for conversion.

The conversation discusses using S5 plus cream (Spironolactone, Alfatradiol, and Tempol) as an alternative to finasteride for hair loss, with concerns about its effectiveness and potential systemic absorption. The original poster already uses 5% minoxidil and is seeking alternatives due to fears of finasteride's side effects.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

PP405 shows promising results for hair density improvement, potentially outperforming Minoxidil in a shorter time. However, its public release is expected around 2029/2030, and its cost and availability remain uncertain.

PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

The user has been using finasteride and minoxidil for five years but continues to experience hair thinning and density loss. They are considering switching to dutasteride for potentially better results.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.